Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CRK antisense RNA 1 (CRK-AS1) is a long noncoding RNA gene that functions as an antisense RNA, expressed from the opposite strand of the protein-coding CRK locus[1][7]. Antisense RNAs regulate gene expression through multiple mechanisms, including transcriptional interference, epigenetic modifications, and post-transcriptional RNA duplex formation[2][8]. These regulatory RNAs typically act in cis (at their site of synthesis) or trans (across different chromosomal loci), influencing their sense gene or nearby genomic regions[2]. While many antisense long noncoding RNAs have been implicated in various cancers and cellular processes such as proliferation and apoptosis[8], there is currently no direct evidence that CRK-AS1 itself serves as a therapeutic target or biomarker. Its biological significance remains an active area of research, especially in the context of epigenetic regulation and gene expression[1][2][8]. In summary, CRK-AS1 is a noncoding regulatory RNA, not a canonical receptor, enzyme, or therapeutic target, and is classified within the growing family of antisense long noncoding RNAs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CRK antisense RNA 1 (CRK-AS1).